Multicenter comparison of cefotetan and cefoxitin in the treatment of acute obstetric and gynecologic infections - PubMed (original) (raw)
Clinical Trial
Multicenter comparison of cefotetan and cefoxitin in the treatment of acute obstetric and gynecologic infections
D L Hemsell et al. Am J Obstet Gynecol. 1988 Mar.
Abstract
Two hundred eighty-seven women were treated in a multicenter, randomized, comparative study to compare the safety and efficacy of cefotetan every 12 hours with that of cefoxitin every 6 or 8 hours in the treatment of acute obstetric and gynecologic pelvic infections. The most frequent primary diagnoses in both groups were endometritis and pelvic inflammatory disease; 24 of these patients were also bacteremic. The mean duration of treatment was 5.2 and 5.4 days for the cefotetan and cefoxitin groups, respectively, and the total doses administered were 18.1 and 32.1 gm, respectively. The rate of clinical failure for the cefotetan group was 8.5% and 12.2% for the cefoxitin group. Laboratory and clinical adverse reactions were infrequent and none was serious; both antimicrobials were well tolerated. These results suggest the administration of cefotetan provided adequate clinical and bacteriologic effectiveness in the treatment of hospital- and community-acquired, polymicrobial obstetric and gynecologic pelvic infections.
Similar articles
- Cefotetan: comparative and noncomparative studies in obstetric and gynecologic infections.
Knuppel RA, O'Bryan D, Lake M. Knuppel RA, et al. South Med J. 1988 Feb;81(2):185-8. South Med J. 1988. PMID: 3422519 Clinical Trial. - Multicenter clinical trials comparing cefotetan with moxalactam or cefoxitin as therapy for obstetric and gynecologic infections.
Sweet RL, Gall SA, Gibbs RS, Hemsell DL, Knuppel RA, Lane TW, Miller RD, Newton ER, Poindexter AN, Reguero W, et al. Sweet RL, et al. Am J Surg. 1988 May 31;155(5A):56-60. doi: 10.1016/s0002-9610(88)80214-9. Am J Surg. 1988. PMID: 3287970 Clinical Trial. - Cefotetan in the treatment of obstetric and gynecologic infections.
Poindexter AN 3rd, Sweet R, Ritter M. Poindexter AN 3rd, et al. Am J Obstet Gynecol. 1986 Apr;154(4):946-50. doi: 10.1016/0002-9378(86)90495-3. Am J Obstet Gynecol. 1986. PMID: 3515949 Clinical Trial. - Role of cephamycins in obstetrics and gynecology.
Sweet RL. Sweet RL. J Reprod Med. 1990 Nov;35(11 Suppl):1064-9. J Reprod Med. 1990. PMID: 2277374 Review. - Cefotetan. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
Ward A, Richards DM. Ward A, et al. Drugs. 1985 Nov;30(5):382-426. doi: 10.2165/00003495-198530050-00002. Drugs. 1985. PMID: 3905336 Review.
Cited by
- Inpatient treatment for uncomplicated and complicated acute pelvic inflammatory disease: ampicillin/sulbactam vs. Cefoxitin.
Hemsell DL, Wendel GD, Hemsell PG, Heard ML, Nobles BJ. Hemsell DL, et al. Infect Dis Obstet Gynecol. 1993;1(3):123-9. doi: 10.1155/S1064744993000286. Infect Dis Obstet Gynecol. 1993. PMID: 18475331 Free PMC article. - Antibiotic regimens for postpartum endometritis.
Mackeen AD, Packard RE, Ota E, Speer L. Mackeen AD, et al. Cochrane Database Syst Rev. 2015 Feb 2;2015(2):CD001067. doi: 10.1002/14651858.CD001067.pub3. Cochrane Database Syst Rev. 2015. PMID: 25922861 Free PMC article. Review. - Ertapenem once a day versus piperacillin-tazobactam every 6 hours for treatment of acute pelvic infections: a prospective, multicenter, randomized, double-blind study.
Roy S, Higareda I, Angel-Muller E, Ismail M, Hague C, Adeyi B, Woods GL, Teppler H; Protocol 023 Study Group. Roy S, et al. Infect Dis Obstet Gynecol. 2003;11(1):27-37. doi: 10.1155/S1064744903000048. Infect Dis Obstet Gynecol. 2003. PMID: 12839630 Free PMC article. Clinical Trial. - The life and times of the Enterococcus.
Murray BE. Murray BE. Clin Microbiol Rev. 1990 Jan;3(1):46-65. doi: 10.1128/CMR.3.1.46. Clin Microbiol Rev. 1990. PMID: 2404568 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical